In children who are subject to migraine attacks, vitamin D supplementation may be an effective and safe adjunctive prophylactic therapy to topiramate, results of a study in Saudi Arabia showed.
In children who are subject to migraine attacks, vitamin D supplementation may be an effective and safe adjunctive prophylactic therapy to topiramate, results of a study in Saudi Arabia showed.
The 56 children (34 girls and 22 boys), who ranged in age from 5 to 14 years had 2 or more headache attacks each week, were not receiving any migraine preventive therapies other than topiramate, and had not taken vitamin D3 supplements within the past 3 months.
The patients were divided into 2 groups. The intervention group received topiramate tablets (2mg per kg of body weight) in 2 daily divided doses along with 5,000 IU of vitamin D3 for 4 consecutive months. The placebo group received only the topiramate along with a placebo.
Investigators observed a good response to treatment in both groups: 76.13% of patients in the intervention group and 53.5% of those in the placebo group.
However, a comparison of migraine characteristics in the 2 groups at the conclusion of the trial showed that D3 supplementation was more effective than placebo in reducing migraine frequency, severity, duration, and disability.
None of the participants experienced serious adverse reactions, though 4 patients in the intervention group and 6 in the placebo group had mild gastrointestinal complaints.
The question of whether vitamin D supplementation is helpful for conditions besides rickets (eg, for asthma), remains open to question, with numerous contradictory studies (similar to the arguments as to whether coffee or alcohol in moderation is good or bad). Consider this a small victory, unconfirmed for now, for vitamin D proponents.
Reference
Elmala MK, Suliman HA, Al-Shokary A, Ibrahim AO, Kamal NM, Elshorbagy HH, Nasef KA, El Din Fathallah MG. The impact of vitamin D3 supplementation to topiramate therapy on pediatric migraine prophylaxis. J Child Neurol. 2022;37(10-11):833-839. doi:10.1177/08830738221092882.
Fluoxetine helps refractory nocturnal enuresis but not for long
March 29th 2023A 12-week study in Egypt of the efficacy of fluoxetine (a selective serotonin reuptake inhibitor) in children with treatment-refractory nocturnal enuresis (NE) found that though the treatment achieved a good initial response, it was not sustainable.
Meet the Board: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI
May 20th 2022Contemporary Pediatrics sat down with one of our newest editorial advisory board members: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI to discuss what led to her career in medicine and what she thinks the future holds for pediatrics.
Meet the board: Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN
April 22nd 2022In the latest episode of our podcast series, Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN shares why she got into medicine, the myths of pediatric, and what the future may hold for the specialty.